Strategic isotope supply RadTran’s technology enables scalable, cost-effective extraction of Ra-224 and Ac-225 from Thorium-232 stockpiles, addressing a critical supply bottleneck for Targeted Alpha Therapies (TAT) that pharmaceutical partners are actively seeking to overcome.

TAT market opportunity The company focuses on enabling TAT-based cancer treatments with lower collateral damage, positioning RadTran to engage oncology drug developers and radiopharma firms pursuing scalable isotope production for next-generation radiopharmaceuticals.

Strategic partnerships Existing collaboration with Energy Fuels indicates a pathway for joint exploration of thorium/radium recovery, suggesting potential for co-development, pilot programs, and early revenue through process integration with established producers.

Proof of concept With patent-protected extraction methods and a clear supply advantage, RadTran can pursue pilot scale demonstrations for pharma developers, accelerating discussions on licensing, manufacturing agreements, and tolling arrangements.

Low company footprint Having a lean team but targeting growth through partnerships and outsourcing, RadTran offers an attractive entry point for strategic services, consulting, and technology licensing without significant internal expansion costs for buyers.